Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
U. N. Wasko, J. Jiang, A. C. Garcia…·R. H Vonderheide
This study evaluates the therapeutic potential of RMC-7977, a broad-spectrum RAS inhibitor, in pancreatic ductal adenocarcinoma models, showing strong anti-tumor effects with minimal impact on normal tissues.
X. Tong, A. S. Patel, E. Kim…·H. Ji
The paper identifies adeno-to-squamous transition (AST) as a mechanism of resistance to KRAS inhibitors in LKB1 mutant lung cancer and links KRT6A expression to poor patient outcomes.
S. Raghavan, P. S. Winter, A. W. Navia…·A. K. Shalek
This study identifies a transitional cancer cell state in metastatic pancreatic cancer and shows that tumor microenvironment signals drive transcriptional plasticity and subtype transitions.
J. M. McFarland, B. R. Paolella, A. Warren…·A. Tsherniak
The paper introduces MIX-Seq, a method for multiplexed single-cell transcriptional profiling of cancer cell responses to perturbations, revealing drug mechanisms and predicting cell viability.
N. Santana-Codina, A. S. Chandhoke, Q. Yu…·J. D. Mancias
This study uses quantitative temporal proteomics to analyze KRASG12C inhibitor responses in cancer models, identifying effective drug combinations to overcome resistance.